BioLife Solutions (NASDAQ:BLFS) EVP Aby Mathew Sells 405 Shares of Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) EVP Aby Mathew sold 405 shares of the company’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $25.59, for a total transaction of $10,363.95. Following the transaction, the executive vice president owned 349,350 shares in the company, valued at approximately $8,939,866.50. The trade was a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

BioLife Solutions Stock Down 1.8%

Shares of NASDAQ:BLFS opened at $24.95 on Friday. The company has a 50-day moving average price of $25.47 and a two-hundred day moving average price of $24.81. BioLife Solutions, Inc. has a twelve month low of $19.10 and a twelve month high of $29.62. The firm has a market capitalization of $1.20 billion, a PE ratio of -356.38 and a beta of 1.93.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. UBS Group restated a “buy” rating on shares of BioLife Solutions in a research report on Monday, December 29th. Zacks Research cut BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Wall Street Zen lowered shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Northland Securities set a $34.00 price objective on shares of BioLife Solutions in a research report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of BioLife Solutions in a report on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $32.00.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently bought and sold shares of BLFS. Tudor Investment Corp ET AL grew its stake in shares of BioLife Solutions by 85.2% during the third quarter. Tudor Investment Corp ET AL now owns 111,356 shares of the medical equipment provider’s stock worth $2,841,000 after acquiring an additional 51,217 shares during the last quarter. Connors Investor Services Inc. acquired a new stake in BioLife Solutions in the 3rd quarter worth approximately $224,000. CIBC Bancorp USA Inc. purchased a new stake in BioLife Solutions during the 3rd quarter worth approximately $1,064,000. PharVision Advisers LLC acquired a new position in BioLife Solutions during the 3rd quarter valued at approximately $316,000. Finally, Quarry LP increased its stake in BioLife Solutions by 50.9% during the 3rd quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock valued at $54,000 after purchasing an additional 713 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Company Profile

BioLife Solutions (NASDAQ:BLFS) specializes in biopreservation and cold chain workflow solutions for cell and gene therapies, regenerative medicine and other advanced biologics. The company develops and markets proprietary cryopreservation media and technology platforms designed to maintain cell viability and functionality during processing, storage and transport. BioLife’s product portfolio addresses critical steps in the manufacturing and distribution of cell-based products, helping life science researchers and biopharmaceutical manufacturers protect and preserve living cells.

The company’s flagship offerings include CryoStor, a family of serum-free cryopreservation media; HypoThermosol, a hypothermic storage solution for short-term cell and tissue preservation; and the ThawSTAR system, an automated cell thawing instrument that delivers controlled and reproducible warming of frozen cell therapies.